Crossmark

Beyond hazard ratios: appropriate statistical methods for quantifying the clinical effectiveness of immune-oncology therapies – the example of the Netherlands

Crossref DOI link: https://doi.org/10.1186/s12874-024-02373-5

Published Online: 2024-10-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Corro Ramos, Isaac

Qendri, Venetia

Al, Maiwenn
Funding

Funding for this research was provided by:

AstraZeneca Netherlands
License Information

Text and Data Mining valid from 2024-10-30

Version of Record valid from 2024-10-30
More Information

Article History

Received: 17 June 2023

Accepted: 16 October 2024

First Online: 30 October 2024

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below